812a Efficacy and Safety of Induction Therapy With the Selective IL-23 Inhibitor BI 655066, in Patients With Moderate-to-Severe Crohn's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Brian G. Feagan(Western University), Wulf O. Böcher(Boehringer Ingelheim (Germany)), Denis Franchimont(McGill University Health Centre), Marc Ferrante(Universitair Ziekenhuis Leuven), William J. Sandborn(University of San Diego), Markus F. Neurath(Friedrich-Alexander-Universität Erlangen-Nürnberg), Julián Panés(Hospital Clínic de Barcelona), Adina Soaita(Boehringer Ingelheim (United States)), Ivona Herichova(Boehringer Ingelheim (Austria)), Steven Padula, Arthur Kaser(University of Cambridge), Geert D’Haens(Amsterdam University Medical Centers), Kyung‐Jo Kim(Asan Medical Center), Édouard Louis(Centre Hospitalier Universitaire de Liège), Sudha Visvanathan, Paul Scholl(Boehringer Ingelheim (United States)), Olivier Dewit, David Hall, Ursula Seidler(Medizinische Hochschule Hannover)
Cited by 14
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k